Monkeypox reported in India – South East Asia Region: Health and economic challenges

Sah, Ranjit; Mohanty, Aroop; Siddiq, Abdelmonem; Singh, Parul; Abdelaal, Abdelaziz; Alshahrani, Najim Z.; Dhama, Kuldeep

doi:10.1016/j.lansea.2022.100063

Cited by 30 publications

(30 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[2][3][4][5]9]. However, this was not predicted that MPX cases will rapidly rise and affect several countries in three months, and will pose global public health emergency [10,11]. As of August 7, 2022, in 88 countries, 28,220 cases were laboratory con rmed globally, with six deaths, and 27.875 cases were reported in countries that have not historically reported MPX.…”

Section: Introductionmentioning

confidence: 99%

Study of knowledge, attitude and anxiety in Kurdistan-region of Iraqi population during the monkeypox outbreak in 2022: An online cross-sectional study

Ahmed

Abdulqadir

Omar

et al. 2022

Preprint

Self Cite

View full text Add to dashboard Cite

Background On July 23, the WHO declared the rapidly spreading monkeypox (MPX) epidemic as a Public Health Emergency of International Concern (PHEIC). This study attempted to assess the knowledge, attitude, and anxiety levels of the general population during the MPX outbreak. Methods An online cross-sectional survey was conducted during the period July 27 and July 30, 2022, using a convenience sampling method. The questionnaire was adapted and developed after an in-depth review of the previous studies. Results A total of 510 respondents participated in this study. 277 (54.3%) were male, 233 (45.7%) were female. Participants had insufficient knowledge of MPX with a mean and SD deviation 2.096 ± 1.359, 2.576 ± 1.466, having a normal attitude toward MPX 4.031 ± 1.645. Moreover, they had anxiety problems 32.382 ± 10.094. There were significant differences in the mean rank scores of the knowledge of respondents about MPX according to their gender, marital status, religion, level of education, and place of residence, with p-values of 0.009, 0.000, 0.000, 0.000, and 0.000, respectively. Also, there were significant differences in the mean rank scores of attitudes of respondents toward MPX according to their gender, level of education, place of residence, and age, with p-values of 0.011, 0.020, and 0.000, 0,029, respectively. Lastly, there were significant differences in the mean rank score of anxiety of respondents toward MPX according to their gender, marital status, religion, level of education, and place of residence, with p-values of 0.000, 0.009, 0.000, 0.000, and 0.000 respectively. Conclusion There is an urgent need to raise public awareness and manage people's emotional wellbeing. Taking into account the alarming scenario of rapid rise in MPX cases in many countries, any feasible pandemic probability of this disease amid the ongoing COVID-19 pandemic, proactive control measures, necessary preventive strategies and preparedness plans need to be executed on priority to counteract this global health emergency as well as safeguard the mental health of the general public. Appropriate policies and effectively prevent and control strategies along with disseminating correct information would explicitly help in counteracting MPX outbreaks and avoiding the infodemic's misinformation and disinformations which could pose unwarranted high fears and panic, and ultimately aid in safeguarding the mental health of the people.

show abstract

Section: Introductionmentioning

confidence: 99%

Study of knowledge, attitude and anxiety in Kurdistan-region of Iraqi population during the monkeypox outbreak in 2022: An online cross-sectional study

Ahmed

Abdulqadir

Omar

et al. 2022

Preprint

Self Cite

View full text Add to dashboard Cite

show abstract

“…Study with phytochemicals is missing in literature; however, our team has published several reviews and editorial paper on monkeypox outbreak with promising insight into future perspectives. [29][30][31][32][33][34] Our present study cannot be compared with previous studies as till date no in silico docking of MPXV with phytochemicals is reported.…”

Section: Molecular Docking Analysismentioning

confidence: 73%

Computational Purposing Phytochemicals against Cysteine Protease of Monkeypox Virus: An In-silico Approach

Bansal¹,

Gupta²,

Sangwan³

et al. 2022

J. Pure Appl. Microbiol.

View full text Add to dashboard Cite

The development and evolution of viruses that cause disease have presented a formidable challenge to contemporary medicine and the global economy, not to mention a catastrophic risk to human health. Almost all of these viruses are zoonotic, meaning they were first identified in animals and then spread to humans. An emerging virus may cause only a few isolated instances, resulting in a limited outbreak, or it may cause widespread infection and spread to other parts of the world, triggering a full-blown epidemic. These kinds of emerging occurrences have occurred frequently and in many different forms during the past few decades. Monkeypox is a zoonotic disease caused by the monkeypox virus, a member of the orthopox family that also includes variola, cowpox, and vaccinia. Both animals and humans can get infected by this virus. Similar to smallpox this disease shows less severe rashes and lower mortality rate. The outbreak of monkeypox was declared a global public health emergency by the World Health Organization in July 2022. Unknown mutations and variations are linked to the recent epidemic. Presently, FDA approved tecovirimat, cidofovir and brincidofovir are there in market to treat monkeypox virus. But there are some side effects of these drugs as they are synthetic. So, scientists are working on natural remedies that can be used as alternative to these drugs. In the present study virtual screening of phytochemicals (N-(2-Allylcarbamoyl-4-chloro-phenyl)-3,4-dimethoxy-benzamide, 6-Dimethylaminonaphthene-1-sulfonicacid amide, Oleic Acid and dipentyl ester) from Allophylus serratus were employed against core viral cysteine proteases from monkeypox virus was done. The docking study revealed that selected ligands bind with target viral protein with binding affinity in the range of -5.0 to -6.7 kcal/mol. N-(2-Allylcarbamoyl-4-chloro-phenyl)-3,4-dimethoxy-benzamide showed the highest binding affinity of -6.7 kcal/mol which can be investigated in the future to design potential drugs against monkeypox virus. Thus, this study foresees the possibility of bioactive phytochemicals functioning as template molecules for further experimental evaluation of their efficiency against monkeypox virus.

show abstract

“…On May 7, 2022, a confirmed case of the West African lineage of MPXV was discovered in the United Kingdom (UK), and subsequently, the MPXV has drawn considerable interest worldwide. United States of America (USA), India, Australia, Canada, Israel, and many European countries, including the UK, Portugal, Sweden, Spain, Italy, France, Germany, Netherlands, and Belgium have all reported cases (CDC 2022a; Sah et al 2022). Since January 1, 2022, nearly 45000 confirmed MPX cases from 96 countries and locations along with 12 deaths have been reported as of August 24, 2022 (Adalja and Inglesby 2022;Adegboye et al 2022;CDC, 2022a;Mohapatra et al 2022).…”

Section: Introductionmentioning

confidence: 99%

Monkeypox: An Update on Current Knowledge and Research Advances

Chandran¹,

Dhama

Aslam

et al. 2022

J Exp Bio & Ag Sci

Self Cite

View full text Add to dashboard Cite

The resurgence of the disease in humans that is very similar to smallpox called monkeypox (MPX) disease, caused by the monkeypox virus (MPXV), is the dominant topic of discussion in the scientific and popular press around the world right now. This is taking place as the world celebrates the historic accomplishments made in the fight against the Coronavirus Disease (COVID-19) pandemic MPX is currently thought to pose a risk to the general public's health, particularly in areas with high rates of MPXV infection and close human-wild animal contact. Despite the rarity of MPX outbreaks, they are often caused by human-to-human transmission, especially in households and healthcare settings. Recent decades have seen recurrent outbreaks of the MPX after the smallpox disease was declared eliminated and the consequent cessation of smallpox vaccination programs. MPX has presently spread to several countries throughout the world and posed a global public health emergency, with nearly 45000 confirmed cases in 96 countries and locations, and 12 deaths as of August 24, 2022. Even though this viral illness is thought to be self-limiting, its consequences and feasible pandemic potential seriously jeopardize public health. The main approach to avoiding MPX is to adopt appropriate prevention and control measures, increase awareness of risk factors, and inform the public of the steps they may take to reduce viral exposure. Scientific studies are currently looking at the viability and suitability of the MPX vaccination. This article presents a general introduction to MPXV / MPX along with progress in diagnosis, treatment, vaccination, and prevention and control strategies for tackling this global health emergency.

show abstract

Monkeypox reported in India – South East Asia Region: Health and economic challenges

Cited by 30 publications

References 3 publications

Study of knowledge, attitude and anxiety in Kurdistan-region of Iraqi population during the monkeypox outbreak in 2022: An online cross-sectional study

Study of knowledge, attitude and anxiety in Kurdistan-region of Iraqi population during the monkeypox outbreak in 2022: An online cross-sectional study

Computational Purposing Phytochemicals against Cysteine Protease of Monkeypox Virus: An In-silico Approach

Monkeypox: An Update on Current Knowledge and Research Advances

Contact Info

Product

Resources

About